The global bronchopulmonary dysplasia treatment market is expected to garner a market value of US$ 385.6 million in 2023 and is expected to accumulate US$ 700.2 million by registering a CAGR of 6.1% in the forecast period.
The market growth is attributed to the increasing cases of bronchopulmonary dysplasia along with the rise in premature births across the globe.
The market registered a CAGR of 5.0% in the historical period 2018 to 2022. Bronchopulmonary dysplasia is a chronic respiratory disease, which most commonly occurs in premature infants who received supplemental oxygen or mechanical ventilation. It is also called respiratory distress syndrome. In addition, bronchopulmonary dysplasia also occurs in infants who experience abnormal lung development or had a pre-birth antenatal infection.
Most infants recover from bronchopulmonary dysplasia, however, some of those have continued lung function and structure abnormalities during adolescence and adulthood. This condition causes serious complications during infancy and requires hospitalization and intensive medical care, during the first 2 years after birth.
The signs and symptoms of BPS include shallow, rapid breathing, chronic cough, shortness of breath, flaring of nostrils while breathing, and discoloration of skin owing to low blood oxygen levels. Many cases of BPD are associated with excess oxygen levels and mechanical ventilation.
The disease is caused by other conditions such as antenatal infection, maternal complications, preeclampsia, and inflammation of the fetal membranes, which affects the development of the lungs.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Long-term side effects of drugs in certain cases are becoming a matter of concern for certain infants. This, in turn, is creating obstacles to market growth. Moreover, the high cost of treatment owing to the complex nature of the disease is another factor impeding the market growth.
Lack of awareness in developing countries leaves many infants undiagnosed. This, in turn, is increasing the death rate of infants. All these factors are derailing the progress of the bronchopulmonary dysplasia treatment sector.
| Attributes | Details |
|---|---|
| Bronchopulmonary Dysplasia Treatment Market CAGR (2023 to 2033) | 6.1% |
| Bronchopulmonary Dysplasia Treatment Market Size (2023) | US$ 385.6 million |
| Bronchopulmonary Dysplasia Treatment Market Size (2033) | US$ 700.2 million |
The global demand for bronchopulmonary dysplasia treatment is projected to increase at a CAGR of 6.1% during the forecast period, reaching a total of US$ 700.2 million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5.0%.
The prevalence of the COVID-19 pandemic brought in the fear of bronchopulmonary dysplasia among healthcare professionals and parents. Thus, the demand for the treatment of the same increased drastically. Moreover, most healthcare facilities are preparing special units for the treatment of bronchopulmonary dysplasia.
Most end-user industries such as nursing homes and hospitals are ready with equipment that help in diagnosing and treating bronchopulmonary dysplasia. This, in turn, is favoring the growth of the market in the assessment period.
Principal Consultant
According to the Airway estimates, in Europe and the United States, up to 160,000 infants are at high risk for the development of BPD collectively, each year. Government initiatives, favorable reimbursement policies, increasing prevalence of bronchopulmonary dysplasia, and a raise in cases of premature births leading to bronchopulmonary dysplasia are boosting the growth of the bronchopulmonary dysplasia treatment market over the forecast period.
Growing research and development activities by pharmaceutical companies to develop innovative treatment options for bronchopulmonary dysplasia boost the market in near future.
Companies are focusing on the development of novel treatment options for bronchopulmonary dysplasia for faster action and quick relief than the conventional dosage forms. For instance, Airway Therapeutics, LLC developed AT-100, a recombinant form of human surfactant protein, for maintaining healthy lung function in infants with bronchopulmonary dysplasia.
On the other hand, research is developing stem cell therapy for novel therapeutic modalities for attenuating BPD severity. Moreover, the first phase I clinical trial of stem cell transplantation for bronchopulmonary dysplasia is successfully conducted by proving its safety and feasibility in preterm infants.
| Countries | Market Share (2022) |
|---|---|
| United States | 35.6% |
| Germany | 7.8% |
| Japan | 3.0% |
North America is expected to dominate the global market for bronchopulmonary dysplasia treatment due to favorable government policies, increased awareness about bronchopulmonary dysplasia, and high treatment rates are expected to drive the growth of the market over the forecast period.
Advancements in the healthcare sector along with continuous research and development in treating bronchopulmonary dysplasia is favoring market growth, especially in the United States. Thus, due to the reasons mentioned above, North America held 41.2% market share in 2022.
| Country | United Kingdom |
|---|---|
| Market CAGR (2023 to 2033) | 5.2% |
Europe is witnessing a growth in the number of infants suffering from bronchopulmonary dysplasia. This is owing to the disease becoming more common in the region. In addition, most cases of bronchopulmonary dysplasia are undiagnosed, increasing the deaths of infants at an alarming rate. This has led to healthcare facilities in the region specifically paying attention to the cause of the diseases.
The strong presence of healthcare sectors in the Netherlands along with government policies working in the favor of childcare are accelerating the growth of the market. Thus, owing to the aforementioned reasons, Europe possessed 37.2% market share in 2022.
| Countries | Market CAGR (2023 to 2033) |
|---|---|
| China | 9.1% |
| India | 7.4% |
With 73.6 million live births in Asia Pacific and a preterm rate of <32 weeks of approximately 2.2%, the demand for bronchopulmonary dysplasia treatment has grown over time. A rise in awareness toward the treatment of the disease and an increase in healthcare expenditure is expected to boost the market growth.
A large patient pool along with government programs and initiatives are the key factors influencing the market growth in Asia Pacific. Thus, Asia Pacific procured a 35% market share in 2022.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The oxygen therapy segment is expected to hold a significant share of the global market during the forecast period due to factors such as the effectiveness of drugs and more commonly used therapy.
In addition, oxygen supplement is an effective therapy with no risks involved and is safe for infants, making it a favorable option for treatment. Thus, supplemental oxygen supplement therapy held a 35.8% market share in 2022.
Based on end-users, the global market is classified into hospitals, nursing homes, critical care units, and others. Amongst these, hospitals are expected to hold a significant share owing to the facilities and equipment they possess.
Most hospitals offer a variety of treatments for bronchopulmonary dysplasia making it feasible for immediate diagnosis and treatments. Thus, hospitals possessed a 47.5% market share in 2022.
Key bronchopulmonary dysplasia treatment start-ups are AyuVis, Exvastat, Altavant Sciences, Atriva Therapeutics, ReAlta Life Sciences, and Omnispirant.
Attention was drawn to modifying treatment regimens in accordance with the unique patient features and severity of the condition. Approaches to personalized medicine aimed to improve results and lessen treatment adverse effects. The pathophysiology of bronchopulmonary dysplasia was extensively researched, and possible treatment targets were found in large part by universities and research organizations. These findings helped to design novel therapeutic strategies and enhance patient outcomes.
The market is forecast to register a CAGR of 6.1% through 2033.
The market is valued to reach US$ 700.2 million by 2033.
The global market advanced at a 5% HCAGR from 2018 to 2022.
The market to secure a valuation of US$ 385.6 million in 2023.
The supplemental oxygen supplement therapy sector comprises 35.8% of the market share.
The hospital category garners 47.5% of the market.
China market is set to expand at a 9.1% CAGR.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 5.3.1. Bronchodilators 5.3.2. Diuretics 5.3.3. Antibiotics 5.3.4. Steroids 5.3.5. Immunomodulators 5.3.6. Surfactant Homeostasis 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033 6.3.1. Nitric Oxide Therapy 6.3.2. Protein Replacement Therapy 6.3.3. Stem Cell Therapy 6.3.4. Supplemental Oxygen 6.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 7.3.1. Hospitals 7.3.2. Nursing Homes 7.3.3. Critical Care Centers 7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Drug Type 9.2.3. By Therapy Type 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Therapy Type 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Type 10.2.3. By Therapy Type 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Therapy Type 10.3.4. By End User 10.4. Key Takeaways 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Drug Type 11.2.3. By Therapy Type 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Therapy Type 11.3.4. By End User 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Drug Type 12.2.3. By Therapy Type 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Therapy Type 12.3.4. By End User 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Drug Type 13.2.3. By Therapy Type 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Therapy Type 13.3.4. By End User 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug Type 14.2.3. By Therapy Type 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Therapy Type 14.3.4. By End User 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Type 15.2.3. By Therapy Type 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Type 15.3.3. By Therapy Type 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Type 16.1.2.2. By Therapy Type 16.1.2.3. By End User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Type 16.2.2.2. By Therapy Type 16.2.2.3. By End User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Type 16.3.2.2. By Therapy Type 16.3.2.3. By End User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Type 16.4.2.2. By Therapy Type 16.4.2.3. By End User 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Type 16.5.2.2. By Therapy Type 16.5.2.3. By End User 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Type 16.6.2.2. By Therapy Type 16.6.2.3. By End User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Type 16.7.2.2. By Therapy Type 16.7.2.3. By End User 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Type 16.8.2.2. By Therapy Type 16.8.2.3. By End User 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Type 16.9.2.2. By Therapy Type 16.9.2.3. By End User 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Type 16.10.2.2. By Therapy Type 16.10.2.3. By End User 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Type 16.11.2.2. By Therapy Type 16.11.2.3. By End User 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Type 16.12.2.2. By Therapy Type 16.12.2.3. By End User 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Type 16.13.2.2. By Therapy Type 16.13.2.3. By End User 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Type 16.14.2.2. By Therapy Type 16.14.2.3. By End User 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Type 16.15.2.2. By Therapy Type 16.15.2.3. By End User 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Type 16.16.2.2. By Therapy Type 16.16.2.3. By End User 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Type 16.17.2.2. By Therapy Type 16.17.2.3. By End User 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Type 16.18.2.2. By Therapy Type 16.18.2.3. By End User 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Type 16.19.2.2. By Therapy Type 16.19.2.3. By End User 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Type 16.20.2.2. By Therapy Type 16.20.2.3. By End User 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Type 16.21.2.2. By Therapy Type 16.21.2.3. By End User 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2022 16.22.2.1. By Drug Type 16.22.2.2. By Therapy Type 16.22.2.3. By End User 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2022 16.23.2.1. By Drug Type 16.23.2.2. By Therapy Type 16.23.2.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Type 17.3.3. By Therapy Type 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Airway Therapeutics LLC 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Chiesi Farmaceutici SpA 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Insmed Incorporated 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. MediPost Co. Ltd. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Meridian Biotech Co. Ltd 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Syntrix Biosystems Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Martindale Pharmaceuticals 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Takeda 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Mallinckrodt 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. AdventHealth 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Bronchopulmonary Dysplasia Treatment Market
